We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

WABC:NASDAQWestamerica Bancorporation Analysis

Data as of 2026-05-10 - not real-time

$54.85

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

The stock is trading at $54.85, comfortably above the 20‑day SMA (54.34) and the 50‑day SMA (52.47), with the 200‑day SMA (49.89) also below, indicating a clear bullish trend. RSI sits at 59.7, well under the overbought threshold, while beta of 0.61 suggests the share is less volatile than the broader market. Volume has been decreasing, yet price remains within a tight range bounded by support at $51.18 and resistance at $56.22, and the market sentiment index reads “Extreme Greed” at 90.73, reflecting strong investor optimism. Technical signals are mixed – the MACD histogram is slightly negative, hinting at short‑term pressure, but the overall moving‑average alignment and price momentum remain positive. Recent earnings released for Q1 2026 show net income of $27.4 million with EPS of $1.13, and the board raised the quarterly dividend to $0.48 per share, a 4% increase. The company boasts a solid PE ratio of 12.2 versus an industry average of 16.4, a dividend yield of 3.39% with a 41% payout ratio, ample cash on hand, and a net‑cash position after debt. Analysts’ target price of $58 implies roughly a 5.7% upside, and the firm has announced an expanded share‑repurchase program, further supporting the valuation case.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish SMA alignment with price above key moving averages
  • Recent earnings beat and dividend increase
  • Slight bearish MACD histogram suggesting short‑term caution

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Undervalued PE relative to industry peers
  • Attractive dividend yield and sustainable payout
  • Analyst target price indicating ~5‑6% upside

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Strong capital position with net cash and low leverage
  • Consistent dividend growth and share‑repurchase program
  • Low beta and defensive positioning in a regional banking niche

Key Metrics & Analysis

Financial Health

Revenue Growth-6.70%
Profit Margin44.30%
P/E Ratio12.2
ROE12.46%
ROA1.90%
P/B Ratio1.5
Industry P/E16.4

Technical Analysis

TrendBullish
RSI59.7
Support$51.18
Resistance$56.22
MA 20$54.34
MA 50$52.47
MA 200$49.89
MACDBearish
VolumeDecreasing
Fear & Greed Index90.73

Valuation

Target Price$58.00
Upside/Downside5.74%
GradeUndervalued
TypeValue
Dividend Yield3.39%

Risk Assessment

Beta0.61
Volatility14.75%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.